Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityActive in the last 2 years

Liang Han

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2803-7804; OpenAlex author ID A5101965700. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
49
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 1 paper · 2014: 4 papers · 2015: 4 papers · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 19

  1. Characterization and treatment of brain metastases from pancreatic cancer: a systematic review. Co-author DOI 10.1007/s12672-025-02623-y↗
  2. Piezo1 act as a potential oncogene in pancreatic cancer progression. Co-author DOI 10.1016/j.lfs.2022.121035↗
  3. The EGFR-HSF1 axis accelerates the tumorigenesis of pancreatic cancer. Co-author DOI 10.1186/s13046-020-01823-4↗
  4. Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling. Co-author DOI 10.3389/fonc.2021.728583↗
  5. Sonic hedgehog signaling pathway promotes pancreatic cancer pain via nerve growth factor. Co-author DOI 10.1136/rapm-2019-100991↗
  6. Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like proper… Last author DOI 10.1002/1878-0261.12399↗
  7. Targeting glypican-4 overcomes 5-FU resistance and attenuates stem cell-like properties via suppression of Wnt/β-catenin pathway in pancreatic cancer cells. Last author DOI 10.1002/jcb.27266↗
  8. Hyperglycemic tumor microenvironment induces perineural invasion in pancreatic cancer. Co-author DOI 10.1080/15384047.2015.1040952↗
  9. Overexpression of Nodal induces a metastatic phenotype in pancreatic cancer cells via the Smad2/3 pathway. Co-author DOI 10.18632/oncotarget.2686↗
  10. Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis. Co-author DOI 10.18632/oncotarget.3663↗
  11. Superoxide dismutase promotes the epithelial-mesenchymal transition of pancreatic cancer cells via activation of the H2O2/ERK/NF-κB axis. Co-author DOI 10.3892/ijo.2015.2938↗
  12. α-Mangostin inhibits hypoxia-driven ROS-induced PSC activation and pancreatic cancer cell invasion. Co-author DOI 10.1016/j.canlet.2014.02.003↗
  13. Upregulated miR-106a plays an oncogenic role in pancreatic cancer. Co-author DOI 10.1016/j.febslet.2014.01.007↗
  14. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signa… Co-author DOI 10.1186/1471-2407-14-686↗
  15. Hyperglycemia regulates TXNIP/TRX/ROS axis via p38 MAPK and ERK pathways in pancreatic cancer. Co-author DOI 10.2174/1568009614666140331231658↗
  16. Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells. Co-author DOI 10.1158/1541-7786.mcr-12-0609↗
  17. The bidirectional interation between pancreatic cancer and diabetes. Last author DOI 10.1186/1477-7819-10-171↗
  18. Relationship between neural alteration and perineural invasion in pancreatic cancer patients with hyperglycemia. Co-author DOI 10.1371/journal.pone.0017385↗
  19. High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR. Co-author DOI 10.1371/journal.pone.0027074↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 17 shared papers, 2011–2022 · strength 1.06
  2. Wanxing Duan · 11 shared papers, 2013–2022 · strength 0.68
  3. Weikun Qian · 5 shared papers, 2018–2025 · strength 0.66
  4. Jiguang Ma · 9 shared papers, 2014–2021 · strength 0.59
  5. Zheng Wang · 6 shared papers, 2013–2025 · strength 0.53
  6. Erxi Wu · 11 shared papers, 2011–2020 · strength 0.52
  7. Ying Xiao · 4 shared papers, 2019–2021 · strength 0.42
  8. Jianjun Lei · 7 shared papers, 2014–2021 · strength 0.41
  9. Jie Li · 4 shared papers, 2018–2021 · strength 0.38
  10. Qinhong Xu · 9 shared papers, 2011–2015 · strength 0.37
  11. Zheng Wu · 5 shared papers, 2014–2022 · strength 0.36
  12. Wei Li · 7 shared papers, 2011–2022 · strength 0.34
  13. Tao Qin · 3 shared papers, 2020–2021 · strength 0.34
  14. Cancan Zhou · 3 shared papers, 2018–2022 · strength 0.31
  15. Kongyuan Wei · 1 shared paper, 2025 · strength 0.27
  16. Hairong He · 1 shared paper, 2025 · strength 0.27
  17. Yan Ma · 1 shared paper, 2025 · strength 0.27
  18. Ke Chen · 3 shared papers, 2018–2021 · strength 0.26
  19. Zeen Zhu · 2 shared papers, 2021–2022 · strength 0.24
  20. Yangyang Yue · 2 shared papers, 2021–2022 · strength 0.24
  21. Xuqi Li · 5 shared papers, 2013–2015 · strength 0.20
  22. Xiongwei Huo · 4 shared papers, 2014–2015 · strength 0.17
  23. Tao Qin · 2 shared papers, 2018–2019 · strength 0.15
  24. Liankang Sun · 2 shared papers, 2018–2019 · strength 0.15
  25. Junyu Cao · 2 shared papers, 2018–2019 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.